NPPA insights

NPPA FAQs: patient assistance undertakings due before October 29

The National Pharmaceutical Pricing Authority (NPPA) has published ten Frequently Asked Questions (FAQs), with answers, on its trade margin rationalization (TMR) order for non-scheduled anti-cancer drugs. The document gives its reference as "TMR notification vide S.O. 5690(E) dated 17.10.2026". NPPA's website lists it as "Frequently Asked Questions (FAQs) on TMR", dated October 23, 2026.

NPPA · October 23, 2026

Vishnu Gupta

The National Pharmaceutical Pricing Authority (NPPA) has published ten Frequently Asked Questions (FAQs), with answers, on its trade margin rationalization (TMR) order for non-scheduled anti-cancer drugs. The document gives its reference as "TMR notification vide S.O. 5690(E) dated 17.10.2026". NPPA's website lists it as "Frequently Asked Questions (FAQs) on TMR", dated October 23, 2026. The two pages print no issue date, number, signature or issuing office of their own.

Annexure-I is live on NPPA's IPDMS portal (answer 1). Manufacturers must submit information in Form V and Annexure-I through IPDMS within seven days of publication of the order, whether or not the MRP changes (answer 2). The newspaper advertisement is required for all products whose prices are reduced and must give the pre-revised and the revised MRP; companies may choose to include products whose MRP is not revised (answer 3). Recalling, relabeling or re-stickering stock released in the market before the revised MRP is implemented is not mandatory if the manufacturer is able to ensure price compliance at the retailer level (answer 8).

The undertakings on the patient assistance program (PAP) under note (d)(ii) and (iii) of the order are to be submitted by all manufacturers initially before October 29, 2026, and again every time there is a revision in MRP; they may be sent to pricing-nppa@gov.in (answer 7). At the request of industry associations, the information in note q(iii) and (iv) of the order may be submitted not later than November 9, 2026, and the note q(iv) information may be provided as on October 31, 2026; it too may be sent to pricing-nppa@gov.in (answer 9). The FAQs refer to these notes by number and do not restate what they require.

Government sales, for the purpose of the order, are sales where the MRP is not printed on the pack, or where it is printed with clear labeling as "For supply to Government; not for sale" (answer 4). No adjustment for sales returns is permissible when calculating net sales for the price to stockist or distributor (PTS/PTD) (answer 5). As note (o) of the order states, TMR for non-scheduled formulations applies to all strengths and dosage forms containing any drug in Table B, alone or in combination, irrespective of dosage strength, dosage form or route of administration, even if the formulation is used for other therapeutic uses (answer 6). The revised prices take effect from November 9, 2026. Where the MRP is revised, a manufacturer may take the annual price increase under paragraph 20(1) of the Drugs (Prices Control) Order, 2013 (DPCO, 2013) from the date the revised price is implemented, which is not later than November 9, 2026; where it is not revised, after 12 months from the last revision in MRP (answer 10).

The FAQs do not give a calendar date for the seven-day filings, do not prescribe a format for the PAP undertakings or the note q(iii) and (iv) information, and do not say what follows if either is late. They do not say how a manufacturer is to show price compliance at the retailer level for stock that is not relabeled.

Issued by
National Pharmaceutical Pricing Authority (NPPA), on its website; the document prints no issuing office
Document
Frequently Asked Questions (FAQs) on TMR: ten questions and answers, with no number or signature of its own
Dated
October 23, 2026, the date NPPA's website gives; the document prints no issue date
Refers to
Order S.O. 5690(E) dated October 17, 2026, on trade margins for non-scheduled anti-cancer drugs
Applies to
Manufacturers under order S.O. 5690(E)
Form V and Annexure-I
Through IPDMS within seven days of publication of the order, whether or not the MRP changes; Annexure-I is live on IPDMS
PAP undertakings, note (d)(ii) and (iii)
Before October 29, 2026, and every time the MRP is revised, to pricing-nppa@gov.in
Note q(iii) and (iv) information
Not later than November 9, 2026, to pricing-nppa@gov.in; the q(iv) information may be provided as on October 31, 2026
Government sales
MRP not printed on the pack, or printed with clear labeling as "For supply to Government; not for sale"
Sales returns
No adjustment in net sales for PTS/PTD
Recall, relabeling or re-stickering
Not mandatory for stock released before the revised MRP, if price compliance at the retailer level is ensured
Revised prices in effect from
November 9, 2026
Annual increase, paragraph 20(1), DPCO, 2013
From the date the revised price is implemented, not later than November 9, 2026; with no MRP revision, 12 months after the last revision

Dated submissions in the FAQs

AnswerWhatBy whenWhere to send it
2Information in Form V and Annexure-IWithin seven days of publication of the order, whether or not the MRP changesThrough IPDMS
7Undertakings on the patient assistance program (PAP) under note (d)(ii) and (iii) of the orderBefore October 29, 2026, and every time there is a revision in MRPpricing-nppa@gov.in
9Information under note q(iii) and (iv) of the orderNot later than November 9, 2026; the note q(iv) information may be provided as on October 31, 2026pricing-nppa@gov.in

The FAQs (PDF, 419 KB)

Source: NPPA's own copy.

Checked against the official copy on October 27, 2026.